ReviewTranslational lung cancer research2025
Advances in immunotherapy for driver gene-positive non-small cell lung cancer: a narrative review.
Review in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- MAML-residual transformer for few-shot prediction of targeted therapy response in NSCLC.Frontiers in cell and developmental biology · 2026Article
- Optimizing PD-1/PD-L1 inhibitors plus chemotherapy for driver mutation-negative non-squamous NSCLC in China: a cost-effectiveness analysis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Although immunotherapy has become the standard treatment for driver gene-negative advanced non-small cell lung cancer (NSCLC), its efficacy in driver gene-positive NSCLC patients remains conversational. This narrative review systematically and critically analyzes recently published literature, aiming to improve the current landscape of immunotherapy for driver gene-positive NSCLC. Methods: The databases of PubMed, Web of Science, Scopus, and Google Scholar were searched for relevant articles, including those published in leading journals and conference proceedings. Search queries were constructed using keywords ("immunotherapy", "non-small cell lung cancer", "driver gene-positive") and their combinations. Literature was included via dual independent screening and team meetings, followed by comprehensive interpretation, resulting in a high-quality literature corpus focused on advances in immunotherapy for driver gene-positive NSCLC. Key Content and Findings: This article reviews the recent advances and challenges in immunotherapy for driver gene-positive NSCLC, focusing on common driver gene mutations. Significant variations exist in how different driver genes regulate the tumor immune microenvironment, leading to disparate immunotherapy response rates. While targeted therapy is the first-line treatment for NSCLC with epidermal growth factor receptor ( Conclusions: Many questions remain about the use of immunotherapy for the treatment of driver gene-positive NSCLC. With optimized biomarker and combination therapies, individualized strategies may be further developed for overcoming drug resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.